Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12129
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLouis, William Jen
dc.contributor.authorDrummer, Olaf Hen
dc.contributor.authorTung, L Hen
dc.date.accessioned2015-05-16T01:46:44Z
dc.date.available2015-05-16T01:46:44Z
dc.date.issued1988-05-16en
dc.identifier.citationJournal of Cardiovascular Pharmacology; 11 Suppl 2(): S5-11en
dc.identifier.govdoc2464095en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12129en
dc.description.abstractIt is not surprising that there has been a search for compounds that combine two useful antihypertensive properties. The expectation is that one such product will offer a simple once-a-day control of blood pressure in a large portion of the population who require drug therapy for their disease. The major disadvantages of the first drug in this class, labetalol, are its poor and variable bioavailability, its relatively short duration of action, and its ability to produce postural hypotension. Attempts to improve the pharmacokinetic deficiencies have given rise to adimolol, which has a prolonged action of up to 90 h in single-dose studies. Of more immediate clinical interest are carvedilol, celiprolol, and dilevalol, each of which appear to have a different mechanism of producing vasodilation. Dilevalol, one of the four isomers of labetalol, is said to form approximately 25% of racemic labetalol. In the pithed rat, both labetalol and dilevalol behave as competitive nonselective beta-blocking drugs but dilevalol, unlike labetalol, shows weak alpha-blocking activity yet produces a dose-dependent fall that is blocked by propranolol, indicating that the drug has a vasodilator action presumably mediated by a beta 2-agonist effect on beta-adrenoceptors. The presence of beta 2-adrenoceptor agonism of this degree makes this drug extremely interesting. Possible advantages include the ability to produce falls in peripheral resistance without significant postural hypotension, and beneficial metabolic effects and effects on plasma lipids compared with traditional beta-adrenoceptor blocking agents that tend to raise blood sugars, interfere with insulin release, lower HDL levels, and raise LDL triglycerides.en
dc.language.isoenen
dc.subject.otherAdrenergic beta-Antagonists.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherAorta, Thoracic.drug effectsen
dc.subject.otherDecerebrate Stateen
dc.subject.otherDose-Response Relationship, Drugen
dc.subject.otherGuinea Pigsen
dc.subject.otherHeart Rate.drug effectsen
dc.subject.otherIn Vitro Techniquesen
dc.subject.otherIsoproterenol.pharmacologyen
dc.subject.otherLabetalol.pharmacologyen
dc.subject.otherMuscle, Smooth.drug effectsen
dc.subject.otherPhenylephrine.pharmacologyen
dc.subject.otherReceptors, Adrenergic.drug effectsen
dc.subject.otherTrachea.drug effectsen
dc.subject.otherVasodilator Agentsen
dc.titleActions of dilevalol on adrenoceptors.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Cardiovascular Pharmacologyen
dc.identifier.affiliationUniversity of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pagesS5-11en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/2464095en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.